New pre-eclampsia test will help increase patient safety
News of a new blood test which promises to detect pre-eclampsia in half the time as current methods is a welcome development says a birth injuries specialist.
The condition, which is developed by around one in ten women in the latter stages of pregnancy, can prove fatal if not diagnosed and monitored appropriately. The new test will be rolled out across the NHS following a study in the Lancet.
Birth injuries lawyer Diane Rostron said: “Pregnancy is a joyful time for many women, but it is essential that both mother and baby are carefully monitored throughout. Pre-eclampsia can prove very dangerous potentially leading to babies being born prematurely or, in more severe cases, can prove fatal if not detected and treated before complications develop.
“The current methods can take up to four days involving both urine and blood pressure tests. The new test promises to detect pre-eclampsia in half the time reducing incidents where patient safety is at risk.”
Pre-eclampsia can occur at any time after 24 weeks to the end of a pregnancy. The NHS advises that early symptoms include high blood pressure and, in some cases, fluid retention causing swelling in the feet, ankles, face and hands.
Other symptoms which may develop include:
- Severe headache
- Problem with sight
- Pain just below the ribs
Diane Rostron continued: “Pregnancy and birth is a precious time but also a time when both mother and baby are at their most vulnerable. Medical innovation at a time when many maternity units across the country are under increasing scrutiny will be a welcome relief for mothers to be.”
Diane Rostron and her team have more than 20 years’ medical negligence experience specialising in birth injuries. Families who have suffered a significant injury before, during or just after birth can contact the team for free initial advice on 01253 766 559.
To read more about the successful outcomes achieved for the families that they have represented visit the website at www.dianerostron.co.uk
Sorry, we are not accepting comments on this article.